Definium Therapeutics (DFTX) Equity Ratio (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Equity Ratio data on file, last reported at 0.69 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.69, down 14.13% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.69 (down 14.13% YoY), and the FY2025 annual result was 0.76, down 5.5% from the prior year.
• Equity Ratio eased to 0.69 in Q1 2026 per DFTX's latest filing, from 0.76 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.93 in Q2 2022 and troughed at 0.55 in Q3 2025.
• A 5-year average of 0.77 and a median of 0.76 in 2025 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio gained 27.37% in 2024, then tumbled 32.77% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.89 in 2022, then dropped by 29.33% to 0.63 in 2023, then climbed by 27.37% to 0.8 in 2024, then declined by 5.5% to 0.76 in 2025, then decreased by 7.98% to 0.69 in 2026.
• Business Quant data shows DFTX's Equity Ratio at 0.69 in Q1 2026, 0.76 in Q4 2025, and 0.55 in Q3 2025.